 |
Davide Brambilla is Associate Professor of drug delivery at the Faculty of Pharmacy at the Université de Montreal, Quebec, Canada. Prof. Brambilla completed his PhD in pharmaceutical technologies at the School of Pharmacy of the University of Paris-Sud (now Paris-Saclay) under the supervision of Professor Patrick Couvreur on the design of nanoparticles for drug delivery applications. In 2012, he joined the laboratory of JC Leroux at Department of Chemistry and Applied Biosciences at the Swiss Federal Institute of Technology in Zurich (ETH) where, after 3 years of post-doctoral stay, he was promoted Group Leader. In 2017, he was appointed Assistant Professor at the Université de Montréal, where he started his research laboratory focused on micro and nanotechnology-based drug delivery tools and diagnostic devices, and teaches the development of biological drugs and pharmacokinetics. In 2022 he was appointed Associate Professor. His laboratory is currently composed of 12 members and mainly focuses on the design of organic nanoparticles for the delivery of genetic materials for gene therapy applications, and the design of polymeric microneedles for diagnostic applications. He pioneered the concept of fluorescent medical micro-tattoos for the non-invasive and wearable monitoring of physiological and pathological parameters.
He is a Junior Research Fellow of Québec Research Fund, the biotherapy Research Chair from the Canadian Generic Pharmaceutical Association and Biosimilars Canada, the current President of the Canadian chapter of the Controlled Release Society, and acts as Assistant Editor of the Journal of Controlled Release. He co-authored over 50 publications in peer-reviewed journals and filed 3 patents. Find out more about Davide’s research on his webpage Follow Davide on Twitter @DBrambilla_Lab |
Read Davide’s Emerging Investigator article, ‘Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression‘, DOI: 10.1039/D2BM00859A
Check out our interview with Davide below:
1. How do you feel about Biomaterials Science as a place to publish research on this topic?
Recent pandemics, and approval of mRNA-nanoparticles vaccines, demonstrated the importance of biomaterials in medicine and the society. This is just the beginning of a revolution driven by new materials toward a precision and personalized medicine. I feel that Biomaterials Science represents the ideal journal for sharing research at the interface of material sciences and medicine.
2. What aspect of your work are you most excited about at the moment and what do you find most challenging about your research?
Nanomedicine and drug delivery have entered in a very exciting phase, where decades of intense research are providing important results. The next decade we will witness impact of this silent revolution in medicine. The biggest challenges will be the translation of the successes of nucleic acid-nanomedicine from the vaccination to the treatment of severe diseases.
3. In your opinion, what are the most important questions to be asked/answered in this field of research?
Costs, efficacy, safety of the new generation treatments.
